CURRENT MATERIALS
Current Materials
Portfolio Managers
Aash M. Shah, CFA
Head of Investments & Sr. Portfolio Manager
BIO
David Harden, Founder
President | Portfolio Manager | Chief Executive Officer | Chief Investment Officer
BIO
Performance1
Total Returns As Of March 31, 2024
*Inception Date: 3/31/2009
SGLIX (Class I) Excess Returns Vs. Benchmark Results (Monthly)
Past performance does not guarantee future results.
Performance for rolling periods other than monthly are different and are available upon request. The monthly rolling periods are calculated based on the strategy return minus the benchmark return. Outperformance is not indicative of positive absolute performance. Rolling periods calculated monthly since inception.
Calendar Year Returns
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
| SGLIX | 13.41% | -13.05% | 15.99% | 4.27% | 24.02% | -2.84% |
| MSCI ACWI LV | 8.34% | -9.82% | 14.49% | 3.40% | 21.79% | -0.98% |
| 2023 | 2022 | 2021 | 2020 | 2019 | |
| SGLIX | 13.41% | -13.05% | 15.99% | 4.27% | 24.02% |
| MSCI ACWI LV | 8.34% | -9.82% | 14.49% | 3.40% | 21.79% |
| 2018 | |
| SGLIX | -2.84% |
| MSCI ACWI LV | -0.98% |
| SGLIX |
| MSCI ACWI LV |
Performance data quoted represents past performance. Past performance does not guarantee future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than the performance shown. Current performance may be lower or higher than that shown here. Total annual operating expense ratios, as stated in the current prospectus, are gross/net respectively: SGLIX 1.01%/0.84%, SGLAX 1.26%/1.09%; SGLOX 2.01%/1.84%. The actual expense ratio is lower due to an expense limitation agreement by the Fund’s investment adviser. Performance would have been lower without fee waivers in effect. Performance is total return and is annualized for periods greater than one year. For performance current to the most recent month-end, please call 855-744-8500. This contractual limitation may not be terminated before December 31, 2023 without the approval of the Board of Directors of The RBB Fund, Inc.
Characteristics
Portfolio Guidelines
- Benchmarked against the MSCI ACWI Minimum Volatility (USD)®
- 80-100 global holdings
- Sector weight constrained to a maximum of 25%
- U.S. exposure constrained to a maximum 65%
- Turnover historically 40-80%
- Lower standard deviation than the benchmark over full market cycles
- Fully invested
- Strong ESG (Environmental, Social, and Governance) considerations
Sector Weights
| Characteristics | SGLIX | MSCI ACWI LV |
| Fund Assets ($ Million) | 105.88 | - |
| Number of Holdings | 88 | 381 |
| Beta* | 0.80 | 0.63 |
| Standard Deviation* (%) | 13.60 | 11.20 |
| Market Cap. ($ Billion) | 43.80 | 52.79 |
| Price to Trailing Earnings | 18.26 | 22.40 |
| Price to Cash Flow | 13.96 | 14.53 |
| Price to Book | 4.00 | 3.86 |
| Enterprise Value to Sales | 2.66 | 3.68 |
| Debt as % of Assets | 18.08 | 26.31 |
| Return on Equity (%) | 18.59 | 16.45 |
| Top 10 Holdings | Ticker | Weight |
| HONDA MOTOR CO LTD-SPONS ADR | HMC | 3.61% |
| ALPHABET INC-CL C | GOOG | 3.60% |
| HERSHEY CO/THE | HSY | 3.52% |
| RIO TINTO PLC-SPON ADR | RIO | 3.18% |
| COLGATE-PALMOLIVE CO | CL | 3.16% |
| VERTEX PHARMACEUTICALS INC | VRTX | 3.06% |
| MICROSOFT CORP | MSFT | 3.01% |
| NICE LTD - SPON ADR | NICE | 2.97% |
| LOCKHEED MARTIN CORP | LMT | 2.60% |
| TAKEDA PHARMACEUTIC-SP ADR | TAK | 2.52% |
* Beta & Standard Deviation 36 months
Fund holdings and sector allocations are subject to change at any time and should not be considered a recommendation to buy or sell any security.
| Risk Statistics Since Inception (February 01, 2017) | SGLIX | MSCI ACWI LV |
| Annualized Standard Deviation | 13.26% | 10.15% |
| Return/Risk | 0.66 | 0.83 |
| Tracking Error | 5.22% | 7.12% |
| R-Squared | 90.64% | 74.26% |
| Alpha | -0.14% | 1.92% |
| Beta | 0.79 | 0.63 |
IMPORTANT INFORMATION
Diversification does not ensure a profit, nor does it protect against a loss in a declining market.
The Fund’s investment objectives, risks, charges, and expenses must be considered carefully before investing. The Prospectus contains this and other important information about the investment companies. A hard copy may be obtained by calling (800) 531-5142. Read the Prospectus carefully before investing.
The Funds are distributed by Quasar Distributors, LLC.
The Funds are offered only to United States residents, and information on this web site is intended only for such persons. Nothing on this web site should be considered a solicitation to buy or an offer to sell shares of any Fund in any jurisdiction where the offer or solicitation would be unlawful under the securities laws of such jurisdiction.
1SGI became the Global Equity Fund’s investment adviser effective January 1, 2017. Returns shown for periods prior to January 1, 2017 were generated under the management of the Global Equity Fund’s former investment adviser.
Effective May 1, 2019, the Summit Global Investments Global Low Volatility Equity Fund was renamed the SGI Global Equity Fund.
SGI Global Equity Fund - Equity securities (stocks) are subject to market, economic, and business risks that will cause their price to rise or fall over time. The net asset value per share of the Fund will fluctuate as the value of the securities in the portfolio change and an investor may lose money. Although the Fund seeks lower volatility, there is no guarantee the Fund will perform as expected. Fund holdings and sector allocations are subject to change and are not recommendations to buy or sell any security. The Fund invests in foreign securities which involve political, economic and currency risks, greater volatility and differences in accounting methods. These risks are greater in emerging markets. The fund may invest in mid-cap companies, which involve additional risks such as limited liquidity and greater volatility than larger companies.
For definitions of terms, please see our Glossary.